Previous reports showed that pretreatment with soluble FKN prior to injury leads to neuroprotection in rodent models of stroke and Parkinson's disease as well as in an ex vivo model of demyelination (Cipriani et al., 2011; O'Sullivan and Dev, 2017; Pabon et al., 2011). Here, CX3CL1 is linked to Parkinson disease.